Goldman Sachs
GNCA

Goldman Sachs’s Genocea Biosciences, Inc. GNCA Stock Holding History

Goldman Sachs’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,881
Closed -$34K – 5938
2018
Q2 		$34K Buy
4,881
+1,878
+63% +$14K ﹤0.01% 5430
2018
Q1 		$25K Buy
+3,003
New +$24.9K ﹤0.01% 5634
2017
Q4 		– Sell
-1,448
Closed -$17K – 6853
2017
Q3 		$17K Buy
+1,448
New +$55K ﹤0.01% 6456
2017
Q1 		– Sell
-1,925
Closed -$63K – 7143
2016
Q4 		$63K Sell
1,925
-2,877
-60% -$94.8K ﹤0.01% 6322
2016
Q3 		$197K Buy
4,802
+1,075
+29% +$42.2K ﹤0.01% 5843
2016
Q2 		$122K Buy
3,727
+2,069
+125% +$75.8K ﹤0.01% 6019
2016
Q1 		$103K Buy
+1,658
New +$52.7K ﹤0.01% 6062
2015
Q4 		– Sell
-2,362
Closed -$129K – 7491
2015
Q3 		$129K Sell
2,362
-961
-29% -$95.3K ﹤0.01% 6316
2015
Q2 		$365K Buy
3,323
+539
+19% +$50K ﹤0.01% 5536
2015
Q1 		$264K Buy
2,784
+180
+7% +$12.7K ﹤0.01% 5763
2014
Q4 		$146K Sell
2,604
-503
-16% -$34.4K ﹤0.01% 6378
2014
Q3 		$225K Buy
3,107
+947
+44% +$104K ﹤0.01% 6050
2014
Q2 		$324K Sell
2,160
-2,268
-51% -$344K ﹤0.01% 5742
2014
Q1 		$644K Buy
+4,428
New +$543K ﹤0.01% 5055

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's GNCA Position: Q3 2018 in Review

Goldman Sachs sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2018, closing a stake of 4,881 shares — an estimated $34K sold.

Goldman Sachs first reported a position in GNCA in Q1 2014 and held it in 14 quarters. The position peaked at $644K in Q1 2014. 48 funds tracked by Wall St. Rank hold GNCA as of Q3 2018.

  • Goldman Sachs reported no remaining Genocea Biosciences, Inc. position as of Q3 2018 after selling out during the quarter.
  • Goldman Sachs sold 4,881 Genocea Biosciences, Inc. shares in Q3 2018, an estimated $34K.
  • Goldman Sachs first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 14 quarters.
  • Goldman Sachs's Genocea Biosciences, Inc. position peaked at $644K in Q1 2014.
  • 48 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2018.

Based on Goldman Sachs's 13F filing for Q3 2018, filed 14 Nov 2018.